Tiger's Eye is a modern hybrid cannabis variety created by crossing Tangie with Wagyu. Suited for both indoor and outdoor cultivation, this strain reaches maturity with a flowering period of 56 days. It is considered a moderate challenge for cultivators, though it rewards that effort with a high yield. Despite its distinct lineage, there are currently no recorded notable offspring derived from this cultivar.

The chemical complexity of Tiger's Eye is defined by a primary presence of myrcene, followed by secondary caryophyllene and limonene. The profile continues with terpinolene, humulene, linalool, beta-pinene, bisabolol, pinene, guaiol, valencene, and isopulegol. This specific terpene arrangement governs the sensory experience, grounding the high-THC content of approximately 19.9 percent while keeping the CBD presence at a minimal 0.05 percent.

Users of Tiger's Eye frequently report feelings of being relaxed, happy, and uplifted. These characteristics make the strain a functional choice for those seeking to address stress, pain, or difficulties with sleep. By balancing a potent THC-dominant cannabinoid profile with a broad spectrum of terpenes, it serves as a precise tool for targeted symptom management rather than casual recreation.